Suzhou Zelgen Biopharmaceuticals Co (SHSE:688266) Inventory-to-Revenue : 1.12 (As of Mar. 2024)

---

Suzhou Zelgen Biopharmaceuticals Co Inventory-to-Revenue Chart

---

Competitive Comparison of Suzhou Zelgen Biopharmaceuticals Co's Inventory-to-Revenue

For the Biotechnology subindustry, Suzhou Zelgen Biopharmaceuticals Co's Inventory-to-Revenue, along with its competitors' market caps and Inventory-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

---

Suzhou Zelgen Biopharmaceuticals Co's Inventory-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Suzhou Zelgen Biopharmaceuticals Co's Inventory-to-Revenue distribution charts can be found below:

* The bar in red indicates where Suzhou Zelgen Biopharmaceuticals Co's Inventory-to-Revenue falls into.

---

Suzhou Zelgen Biopharmaceuticals Co Inventory-to-Revenue Calculation

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Suzhou Zelgen Biopharmaceuticals Co's Inventory-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Suzhou Zelgen Biopharmaceuticals Co's Inventory-to-Revenue for the quarter that ended in Mar. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

---

Suzhou Zelgen Biopharmaceuticals Co  (SHSE:688266) Inventory-to-Revenue Explanation

An increase in Inventory-to-Revenue from one quarter to the next indicates that one of the following is happening:

1. investment in inventory is growing more rapidly than revenue
2. revenue are dropping
No matter which situation is causing the problem, an increase in the Inventory-to-Revenue may signal an oncoming cash flow problem.

Likewise, a decrease in the Inventory-to-Revenue from one quarter to next indicates that one of these is occurring:

1. investment in inventory is shrinking in relation to revenue
2. revenue are increasing
No matter which situation is causing the reduction in the Inventory-to-Revenue, either one suggests that business's inventory levels and its cash flow are effectively managed.

More Related Terms:

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Suzhou Zelgen Biopharmaceuticals Co's Days Inventory for the three months ended in Mar. 2024 is calculated as:

2. Inventory Turnover measures how fast the company turns over its inventory within a year.

Suzhou Zelgen Biopharmaceuticals Co's Inventory Turnover for the quarter that ended in Mar. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

---

Suzhou Zelgen Biopharmaceuticals Co Inventory-to-Revenue Related Terms

Thank you for viewing the detailed overview of Suzhou Zelgen Biopharmaceuticals Co's Inventory-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Total Inventories Revenue Days Inventory Cost of Goods Sold Inventory Turnover

---

Suzhou Zelgen Biopharmaceuticals Co (SHSE:688266) Business Description

Executives

Zhang Bin	Core technical personnel
Huang Gang	senior management
Lv Bin Hua	Directors, senior managers, core technical personn
Lu Hui Ping	Directors, senior managers
Gao Qing Ping	senior management
Wu Ji Sheng	Directors, senior managers, core technical personn
Zhang Jun Li	senior management
Wu Li Qing	Core technical personnel
	Core technical personnel
Sheng Ze Lin	Directors, senior managers, core technical personn